

Date of report: 20 July 2022

Abbreviated name of the Issuer:

MABION S.A.

Subject: Extension of cooperation with Novavax

Legal basis:

Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 on the conclusion of an agreement with Novavax, Inc. ("Novavax") relating to a commercial contract manufacturing agreement ("Manufacturing Agreement") and subsequent current reports on the extension of cooperation with Novavax, the Management Board of Mabion S.A. ("Company") hereby informs that on 20 July 2022 it signed with Novavax another extension of the scope of services under the Manufacturing Agreement in the form of Statement of Work #7 ("SOW#7").

The scope of SOW#7 covers the manufacturing by the Company of the cell banks carrying genetic structures which will serve the implementation of processes of the production of the active ingredient for one of Novavax preparations.

The banks will be manufactured in the GMP (Good Manufacturing Practice) environment. The produced material will then be subjected to appropriate analytical tests, after which it will be transferred to Novavax for its needs.

The implementation of works covered by SOW#7 will begin immediately after signing the order.